medigraphic.com
ISSN 1561-3070 (Digital)

2021, Número 4

<< Anterior Siguiente >>

Rev Cub Oftal 2021; 34 (4)


Novedades del glaucoma en tiempos de COVID-19

Arzuaga HE, Fumero GFY, Batista PM, Domínguez RM, Pérez RY

Idioma: Español
Referencias bibliográficas: 29
Paginas: 1-18
Archivo PDF: 336.38 Kb.


RESUMEN

El impacto de la COVID-19 en la atención médica dominó las noticias en 2020, incluida la atención del glaucoma. Sin embargo, el reciente cambio de paradigma en la terapia de esta patología hacia una intervención más temprana, un mejor manejo del cumplimiento del paciente y un nuevo enfoque en abordar la patología real, continuó avanzando en este periodo con la aprobación de nuevos medicamentos, productos biológicos y dispositivos, que significaron avances en la atención médica. En este artículo, pretendemos reflexionar sobre los logros obtenidos en el año 2020 en el tratamiento del glaucoma, así como brindar una descripción general de los hallazgos más notables. Se realizó una búsqueda sistemática de la literatura científica de mayor impacto. Se limitó la búsqueda por tipo de diseño (revisiones, series de casos, estudios descriptivos, analíticos y experimentales, metanálisis). No se tuvo en cuenta el idioma de la publicación.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kim CY, Park KH, Ahn J, Ahn MD, Cha SC, Kim HS, et al. Treatment patterns and medication adherence of patients with glaucoma in South Korea. Br J Ophthalmol. 2017;101(6):801-7. DOI: https://doi.org/10.1136/bjophthalmol-2016-308505

  2. Cvenkel B, Kolko M. Current medical therapy and future trends in the management of glaucoma treatment. J Ophthalmol. 2020;2020. DOI: https://doi.org/10.1155/2020/6138132

  3. Shirley M. Bimatoprost implant: first approval. Drugs Aging. 2020;37(6):457-62. DOI: https://doi.org/10.2165/00002512-199915050-00001

  4. Lee SS, Dibas M, Almazan A, Robinson MR. Dose-response of intracameral bimatoprost sustained-release implant and topical bimatoprost in lowering intraocular pressure. J Ocul Pharmacol Ther. 2019;35(3):138-44. DOI: https://doi.org/10.1089/jop.2018.0095

  5. Medeiros FA, Walters TR, Kolko M, Coote M, Bejanian M, Goodkin ML, Guo Q, Zhang J, Robinson MR, Weinreb RN, et al. Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1). Ophthalmology. 2020;127(12):1627-41. DOI: https://doi.org/10.1016/j.ophtha.2020.06.018

  6. Craven ER, Walters T, Christie WC, et al. 24-month phase I/II clinical trial of bimatoprost sustained-release implant (Bimatoprost SR) in glaucoma patients. Drugs. 2020;80(2):167-79. DOI: https://doi.org/10.1007/s40265-019-01248-0

  7. Lewis RA, Christie WC, Day DG, et al. Bimatoprost sustained-release implants for glaucoma therapy: 6-month results from a phase I/II clinical trial. Am J Ophthalmol. 2017;175:137-47. DOI: https://doi.org/10.1016/j.ajo.2016.11.020

  8. Seal JR, Robinson MR, Burke J, et al. Intracameral sustained-release bimatoprost implant delivers bimatoprost to target tissues with reduced drug exposure to off-target tissues. J Ocul Pharmacol Ther. 2019;35(1):50-7. DOI: https://doi.org/10.1089/jop.2018.0067

  9. Ibach M. Interim results of a prospective phase II study of travoprost intraocular implants. San Antonio, Texas: American Academy of Optometry Annual Meeting; 2018.

  10. Rady J. A novel, long-term, sustainable drug delivery platform. San Francisco: Glaucoma 360: New Horizons Forum; 2020.

  11. Gazzard G, Konstantakopoulou E, Garway-Heath D, Garg A, Vickerstaff V, Hunter R, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. The Lancet. 2019;393(10180):1505-16. DOI: https://doi.org/10.1016/S0140-6736(18)32213-X

  12. Belkin M, Geffen N, Ofir S, Kaplan Messas A, Barkana Y, Belkin A, et al. Direct trans-scleral selective laser trabeculoplasty (SLT) without a gonioscopy lens. Invest Ophthalmol Vis Sci. 2014 [acceso: 15/11/2021];55(13):819. Disponible en: https://iovs.arvojournals.org/article.aspx?articleid=2146507

  13. Sacks ZS, Dobkin-Bekman M, Geffen N, Goldenfeld M, Belkin M. Non-contact direct selective laser trabeculoplasty: light propagation analysis. Biomed Opt Express. 2020;11(6):2889-904. DOI: https://doi.org/10.1364/BOE.390849

  14. Goldenfeld M, Belkin M, Dobkin-Bekman M, Sacks Z, Meirovitch SB, Geffen N, et al. Automated direct selective laser trabeculoplasty: first prospective clinical trial. Trans Vis Sci Tech. 2021;10(3):1-11. DOI: https://doi.org/10.1167/tvst.10.3.5

  15. Roy S, Villamarin A, Stergiopulos C, Bigler S, Guidotti J, Stergiopulos N, Kniestedt C, Mermoud A. Initial Clinical Results of the eyeWatch: a New Adjustable Glaucoma Drainage Device Used in Refractory Glaucoma Surgery. J Glauc. 2019;28(5):452-8. DOI: https://doi.org/10.1097/IJG.0000000000001209

  16. Villamarin A, Roy S, Bigler S, Stergiopulos N. A new adjustable glaucoma drainage device. Invest Ophthalmol Vis Sci. 2014;25;55(3):1848-52. DOI: https://doi.org/10.1167/iovs.13-12626

  17. Ammar DA, Seibold LK, Kahook MY. Preclinical investigation of goniotomy using four different techniques. Clin Ophthalmol. 2020;28(14):3519-25. DOI: https://doi.org/10.2147/OPTH.S281811

  18. Eurotimes. A Cataract Surgeon's Guide to iStent inject W: Improving outcomes and quality of life in cataract patients with mild-to-moderate open-angle glaucoma. Eurot Suppl. 2019:1-10. Disponible en: https://www.eurotimes.org

  19. Cela D. Safety and efficacy of iStent Inject(r) trabecular micro-bypass stents during phacoemulsification for open-angle glaucoma associated with cataract. Francia, Paris. Poster presentation, 37 Congress of the ESCRS; 2019.

  20. Marko P. Efficacy and adverse event profile of the istent and istent inject trabecular micro-bypass for open-angle glaucoma: A Meta-analysis. J Curr Glauc Pract. 2018;12(2):67-84. DOI: https://doi.org/10.5005/jp-journals-10008-1248

  21. Pinchuk L, Riss I, Batlle JF, et al. The development of a micro-shunt made from poly (styrene-block-isobutylene-block-styrene) to treat glaucoma. J Biomed Mater Res B Appl Biomater. 2017;105(1):211-21. DOI: https://doi.org/10.1002/jbm.b.33525

  22. Kerr NM, Ahmed IIK, Pinchuk L, Sadruddin O, Palmberg PF. PRESERFLO MicroShunt. Minim Inv Glauc Surg. 2020 [acceso: 15/11/2020]. pp. 91-103. Disponible en: https://link.springer.com/chapter/10.1007/978-981-15-5632-6_7

  23. Batlle JF, Corona A, Albuquerque R. Long-term results of the PRESERFLO(r) MicroShunt in Patients with Primary Open-angle Glaucoma from a Single-center Non-randomized Study. J Glauc. 2021;30(3):281-6. DOI: https://doi.org/10.1097/IJG.0000000000001734

  24. ClinicalTrials.gov. NCT02177123. Post market study of the InnFocus MicroShunt. ClinicalTrials.gov. 2018 [acceso: 15/11/2020]. Disponible en: https://www.clinicaltrials.gov/ct2/show/NCT02177123

  25. ClinicalTrials.gov. NCT00772330. Clinical study of the safety and performance of the Miami InnFocus Drainage Implant to relieve glaucoma symptoms. ClinicalTrials.gov; 2019 [acceso: 15/11/2020]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT00772330

  26. ClinicalTrials.gov.NCT01881425. InnFocus MicroShunt versus trabeculectomy study (IMS). ClinicalTrials.gov; 2019 [acceso: 15/11/2020]. Disponible en: http://www.clinicaltrials.gov/ct2/show/NCT01881425

  27. iStent infinite. Powerful Standalone MIGS Indication. Glaukos Corporation; 2021 [acceso: 14/10/2021]. Disponible en: http://s21.q4cdn.com/471661912/files/doc_presentations/2021/Glaukos-Investor-Presentation_January-2021_vFF.pdf

  28. Keel S. The eye in artificial intelligence in Ophthalmology. Clin Exp Ophthalmol. 2019 [acceso: 15/11/2020];47(1):5-6. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30485615/

  29. Mayro EL, Wang M, Elze T, Pasquale LR. The impact of artificial intelligence in the diagnosis and management of glaucoma. Eye (Lond). 2020;34(1):1-11. DOI: https://doi.org/10.1038/s41433-019-0577-x




2020     |     www.medigraphic.com